Does Rallies show 13F holders for KROS?

Yes. Rallies tracks hedge fund and 13F ownership data for KROS, including fund names, share counts, latest tracked quarter, and position changes when available.

Is KROS research on Rallies investment advice?

No. Rallies provides research, data, and educational context for KROS. It does not provide personalized investment advice.

KROS (Keros Therapeutics, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Keros Therapeutics, Inc. Common Stock (KROS) is a publicly traded Healthcare sector company. As of May 21, 2026, KROS trades at $10.98 with a market cap of $201.09M and a P/E ratio of 4.57. KROS moved +11.10% today. Year to date, KROS is -38.73%; over the trailing twelve months it is -22.35%. Its 52-week range spans $9.12 to $72.37. Analyst consensus is buy with an average price target of $21.20. Rallies surfaces KROS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns KROS stock?

Hedge funds tracked by Rallies that own KROS include Orbimed Advisors, Mangrove Partners, Redmile Group, and Panagora Asset. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Keros Therapeutics, Inc. Common Stock.

KROS Key Metrics

Key financial metrics for KROS
Metric	Value
Price	$10.98
Market Cap	$201.09M
P/E Ratio	4.57
EPS	$2.34
Dividend Yield	0.00%
52-Week High	$72.37
52-Week Low	$9.12
Volume	0
Avg Volume	0
Revenue (TTM)	$243.86M
Net Income	$87.01M
Gross Margin	0.00%

Top Hedge Funds Holding KROS

Orbimed Advisors holds 759.15K shares of KROS, changed -5.60% as of Mar 31, 2026.
Mangrove Partners holds 736.38K shares of KROS, changed +156.58% as of Dec 31, 2024.
Redmile Group holds 552.51K shares of KROS, changed +0.00% as of Sep 30, 2025.
Panagora Asset holds 34.66K shares of KROS, changed -71.78% as of Mar 31, 2026.

Latest KROS News

Keros Therapeutics Reports $23.7M Q1 Loss, R&D Costs Fall 67% on Takeda Transition — May 14, 2026
Keros Therapeutics Launches Phase 2 ALS Trial Design with Healey ALS MyMatch — Mar 9, 2026
Keros Therapeutics Triggers $10M Milestone with Phase III RENEW Trial Start — Mar 5, 2026
Keros to Launch DMD Trial and Pursue ALS Phase II, Backed by $200M Takeda Deal — Feb 28, 2026
Keros Therapeutics Cuts 45% Staff, Shelves Cibotercept to Fund KER-065 Phase II Trial — Jan 16, 2026

Recent KROS Insider Trades

BIENAIME JEAN JACQUES bought 1.00K (~$11.70K) on Apr 15, 2026.
BIENAIME JEAN JACQUES bought 2.00K (~$22.42K) on Mar 9, 2026.
Seehra Jasbir sold 7.01K (~$113.43K) on Feb 19, 2026.

KROS Analyst Consensus

8 analysts cover KROS: 0 strong buy, 5 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $21.20.

Common questions about KROS

Who owns KROS stock?: Hedge funds tracked by Rallies that own KROS include Orbimed Advisors, Mangrove Partners, Redmile Group, and Panagora Asset. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Keros Therapeutics, Inc. Common Stock.
Does Rallies show 13F holders for KROS?: Yes. Rallies tracks hedge fund and 13F ownership data for KROS, including fund names, share counts, latest tracked quarter, and position changes when available.
Is KROS research on Rallies investment advice?: No. Rallies provides research, data, and educational context for KROS. It does not provide personalized investment advice.